Project description:Mutations in isocitrate dehydrogenase 2 (IDH2) occur in many cancers including Acute Myeloid Leukemia (AML). In preclinical models mutant IDH2 causes partial hemopoietic differentiation arrest. Recently, we showed that single agent Enasidenib, a first-in-class, selective mutant IDH2 inhibitor, produces a 40% response in relapsed/refractory AML patients by promoting differentiation. Yet, the rate, extend and duration of the clinical benefits of Enasidenib vary from one patient to another. To investigate how the genetic mutational landscape, at baseline or at relapse, contributes in modulating response to Enasidenib, WES analyses on FACS-sorted blasts from baseline, best response and/or relapse samples from 16 Enasidenib-treated patients were performed. WES analyses were also performed on the CD3+ cells from the same patients, which may be used as germinal control samples.
Project description:CTCF ChIP-seq of 39 primary samples derived from human acute leukemias, namely AML, T-ALL and mixed myeloid/lymphoid leukemias with CpG Island Methylator Phenotype (CIMP). Due to patient confidentiality considerations, the raw data files for this dataset have been deposited to the EGA controlled-access archive under the accession numbers EGAS00001007094 (study); EGAD00001011059 (dataset).
Project description:H3K27ac ChIP-seq of 79 primary samples derived from human acute leukemias, namely AML, T-ALL and mixed myeloid/lymphoid leukemias with CpG Island Methylator Phenotype (CIMP). In addition, 4 samples derived from CD34+ cord blood cells of healthy donors were included. Due to patient confidentiality considerations, the raw data files for this dataset have been deposited to the EGA controlled-access archive under the accession numbers EGAS00001007094 (study); EGAD00001011060 (dataset).
Project description:In this study, we employed a hypothesis-free and data-driven analytical approach to investigate the CSF proteome in 29 patients with SLE. Herein, our aim was to explore the CSF proteome with data-independent acquisition mass spectrometry (DIA-MS) and cluster SLE patients based on their CSF proteomic patterns. In addition, we aimed to investigate the relationship between protein patterns and a comprehensive clinical dataset including demographic variables, medical history, clinical rheumatologic and neurologic disease manifestations, neurocognitive functionality, cerebral MRI and laboratory measurements.The proteomic data was used for sample clustering and clusters were analyzed for clinical dataset variance. Proteins were clustered in modules using Weighted Gene Co-expression Correlation Network Analysis (WGCNA) and modules were biologically characterized and analyzed for correlation to the clinical dataset. Three patient clusters were identified. Cluster 1 was characterized by the highest frequency of nephritis, depression, and cognitive dysfunction. Cluster 2 showed the highest frequency of alopecia and SSA-antibodies, and a low frequency of cognitive impairment. Cluster 3 had a higher frequency of autonomic neuropathy and lupus headache. Six protein modules were identified (M1-M6). The modules were characterized by nervous tissue proteins (M1), CNS lipoproteins (M2), macrophage proteins (M3), plasma proteins (M4), immunoglobulins (M5), and intracellular metabolic proteins (M6). Module 1 and M2 proteins were most abundant in patient cluster 1 and correlated with nephritis, depression and cognitive impairment. Increased abundance of M4 and M5 proteins were most distinct in patient cluster 2 and inversely correlated to cognitive impairment and brain atrophy. We conclude that patients clustered by their CSF proteomic pattern had different disease phenotypes. Nephritis and neuronal damage defined the group with higher levels of neuronal proteins in CSF, which may suggest shared pathogenetic pathways in SLE affecting the kidney and CNS.